01Recent Phase III trial results showed a 25% improvement in patient outcomes compared to standard therapies, positioning Soiken for potential market leadership.
02A new licensing agreement with a major pharmaceutical company could generate an additional $200M in revenue over the next three years.
03The company is exploring new markets in Southeast Asia, which could expand its addressable market by 30%.
04Oncology innovation
05Biotechnology partnerships
06FDA approvals for new oncology drugs
07Partnership announcements with larger pharmaceutical companies
